{"id":"https://openalex.org/W4367668398","doi":"https://doi.org/10.1007/s40273-023-01272-9","title":"Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal","display_name":"Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal","publication_year":2023,"publication_date":"2023-05-02","ids":{"openalex":"https://openalex.org/W4367668398","doi":"https://doi.org/10.1007/s40273-023-01272-9","pmid":"https://pubmed.ncbi.nlm.nih.gov/37129774","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/10322744"},"language":"en","primary_location":{"id":"doi:10.1007/s40273-023-01272-9","doi":"https://doi.org/10.1007/s40273-023-01272-9","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1007/s40273-023-01272-9","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40273-023-01272-9.pdf","source":{"id":"https://openalex.org/S43019230","display_name":"PharmacoEconomics","issn_l":"1170-7690","issn":["1170-7690","1179-2027"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PharmacoEconomics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s40273-023-01272-9.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003126498","display_name":"Willem J. A. Witlox","orcid":"https://orcid.org/0000-0003-1007-4284","observed_orcids":["https://orcid.org/0000-0003-1007-4284"]},"institutions":[{"id":"https://openalex.org/I2800191616","display_name":"Maastricht University Medical Centre","ror":"https://ror.org/02d9ce178","country_code":"NL","type":"funder","lineage":["https://openalex.org/I2800191616"]},{"id":"https://openalex.org/I34352273","display_name":"Maastricht University","ror":"https://ror.org/02jz4aj89","country_code":"NL","type":"education","lineage":["https://openalex.org/I34352273"]},{"id":"https://openalex.org/I4405268545","display_name":"Care and Public Health Research Institute","ror":"https://ror.org/01930wn69","country_code":"NL","type":"facility","lineage":["https://openalex.org/I34352273","https://openalex.org/I4405268545"]}],"countries":["NL"],"is_corresponding":true,"raw_author_name":"Willem Witlox","raw_affiliation_strings":["Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands. willem.witlox@mumc.nl","Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands. willem.witlox@mumc.nl","Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands"],"raw_orcid":"https://orcid.org/0000-0003-1007-4284","affiliations":[{"raw_affiliation_string":"Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands. willem.witlox@mumc.nl","institution_ids":["https://openalex.org/I34352273","https://openalex.org/I4405268545"]},{"raw_affiliation_string":"Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands. willem.witlox@mumc.nl","institution_ids":["https://openalex.org/I2800191616"]},{"raw_affiliation_string":"Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands","institution_ids":["https://openalex.org/I2800191616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057351979","display_name":"Sabine Elisabeth Grimm","orcid":"https://orcid.org/0000-0002-2175-7999","observed_orcids":["https://orcid.org/0000-0002-2175-7999"]},"institutions":[{"id":"https://openalex.org/I2800191616","display_name":"Maastricht University Medical Centre","ror":"https://ror.org/02d9ce178","country_code":"NL","type":"funder","lineage":["https://openalex.org/I2800191616"]},{"id":"https://openalex.org/I34352273","display_name":"Maastricht University","ror":"https://ror.org/02jz4aj89","country_code":"NL","type":"education","lineage":["https://openalex.org/I34352273"]},{"id":"https://openalex.org/I4405268545","display_name":"Care and Public Health Research Institute","ror":"https://ror.org/01930wn69","country_code":"NL","type":"facility","lineage":["https://openalex.org/I34352273","https://openalex.org/I4405268545"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Sabine Grimm","raw_affiliation_strings":["Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands","Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands","institution_ids":["https://openalex.org/I34352273","https://openalex.org/I4405268545"]},{"raw_affiliation_string":"Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands","institution_ids":["https://openalex.org/I2800191616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035838625","display_name":"Jeremy Howick","orcid":"https://orcid.org/0000-0003-0280-7206","observed_orcids":["https://orcid.org/0000-0003-0280-7206"]},"institutions":[{"id":"https://openalex.org/I4210088647","display_name":"Kleijnen Systematic Reviews (United Kingdom)","ror":"https://ror.org/004g82f36","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210088647"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jeremy Howick","raw_affiliation_strings":["Kleijnen Systematic Reviews Ltd, York, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kleijnen Systematic Reviews Ltd, York, UK","institution_ids":["https://openalex.org/I4210088647"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059685514","display_name":"Nigel Armstrong","orcid":"https://orcid.org/0000-0002-7443-4798","observed_orcids":["https://orcid.org/0000-0002-7443-4798"]},"institutions":[{"id":"https://openalex.org/I4210088647","display_name":"Kleijnen Systematic Reviews (United Kingdom)","ror":"https://ror.org/004g82f36","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210088647"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Nigel Armstrong","raw_affiliation_strings":["Kleijnen Systematic Reviews Ltd, York, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kleijnen Systematic Reviews Ltd, York, UK","institution_ids":["https://openalex.org/I4210088647"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031695309","display_name":"Charlotte Ahmadu","orcid":"https://orcid.org/0000-0001-6420-9071","observed_orcids":["https://orcid.org/0000-0001-6420-9071"]},"institutions":[{"id":"https://openalex.org/I4210088647","display_name":"Kleijnen Systematic Reviews (United Kingdom)","ror":"https://ror.org/004g82f36","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210088647"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Charlotte Ahmadu","raw_affiliation_strings":["Kleijnen Systematic Reviews Ltd, York, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kleijnen Systematic Reviews Ltd, York, UK","institution_ids":["https://openalex.org/I4210088647"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Kevin McDermott","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088647","display_name":"Kleijnen Systematic Reviews (United Kingdom)","ror":"https://ror.org/004g82f36","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210088647"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Kevin McDermott","raw_affiliation_strings":["Kleijnen Systematic Reviews Ltd, York, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kleijnen Systematic Reviews Ltd, York, UK","institution_ids":["https://openalex.org/I4210088647"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041959705","display_name":"Thomas Otten","orcid":"https://orcid.org/0000-0002-6390-5638","observed_orcids":["https://orcid.org/0000-0002-6390-5638"]},"institutions":[{"id":"https://openalex.org/I2800191616","display_name":"Maastricht University Medical Centre","ror":"https://ror.org/02d9ce178","country_code":"NL","type":"funder","lineage":["https://openalex.org/I2800191616"]},{"id":"https://openalex.org/I34352273","display_name":"Maastricht University","ror":"https://ror.org/02jz4aj89","country_code":"NL","type":"education","lineage":["https://openalex.org/I34352273"]},{"id":"https://openalex.org/I4405268545","display_name":"Care and Public Health Research Institute","ror":"https://ror.org/01930wn69","country_code":"NL","type":"facility","lineage":["https://openalex.org/I34352273","https://openalex.org/I4405268545"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Thomas Otten","raw_affiliation_strings":["Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands","Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands","institution_ids":["https://openalex.org/I34352273","https://openalex.org/I4405268545"]},{"raw_affiliation_string":"Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands","institution_ids":["https://openalex.org/I2800191616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051240644","display_name":"Caro Noake","orcid":"https://orcid.org/0000-0003-0329-4772","observed_orcids":["https://orcid.org/0000-0003-0329-4772"]},"institutions":[{"id":"https://openalex.org/I4210088647","display_name":"Kleijnen Systematic Reviews (United Kingdom)","ror":"https://ror.org/004g82f36","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210088647"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Caro Noake","raw_affiliation_strings":["Kleijnen Systematic Reviews Ltd, York, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kleijnen Systematic Reviews Ltd, York, UK","institution_ids":["https://openalex.org/I4210088647"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090941567","display_name":"Robert F. Wolff","orcid":"https://orcid.org/0000-0003-3270-7791","observed_orcids":["https://orcid.org/0000-0003-3270-7791"]},"institutions":[{"id":"https://openalex.org/I4210088647","display_name":"Kleijnen Systematic Reviews (United Kingdom)","ror":"https://ror.org/004g82f36","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210088647"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Robert Wolff","raw_affiliation_strings":["Kleijnen Systematic Reviews Ltd, York, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kleijnen Systematic Reviews Ltd, York, UK","institution_ids":["https://openalex.org/I4210088647"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021404933","display_name":"Manuela A. Joore","orcid":"https://orcid.org/0000-0002-5649-6768","observed_orcids":["https://orcid.org/0000-0002-5649-6768"]},"institutions":[{"id":"https://openalex.org/I2800191616","display_name":"Maastricht University Medical Centre","ror":"https://ror.org/02d9ce178","country_code":"NL","type":"funder","lineage":["https://openalex.org/I2800191616"]},{"id":"https://openalex.org/I34352273","display_name":"Maastricht University","ror":"https://ror.org/02jz4aj89","country_code":"NL","type":"education","lineage":["https://openalex.org/I34352273"]},{"id":"https://openalex.org/I4405268545","display_name":"Care and Public Health Research Institute","ror":"https://ror.org/01930wn69","country_code":"NL","type":"facility","lineage":["https://openalex.org/I34352273","https://openalex.org/I4405268545"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Manuela Joore","raw_affiliation_strings":["Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands","Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands","institution_ids":["https://openalex.org/I34352273","https://openalex.org/I4405268545"]},{"raw_affiliation_string":"Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands","institution_ids":["https://openalex.org/I2800191616"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5003126498"],"corresponding_institution_ids":["https://openalex.org/I2800191616","https://openalex.org/I34352273","https://openalex.org/I4405268545"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":{"value":4390,"currency":"USD","value_usd":4390},"fwci":0.5921,"has_fulltext":true,"cited_by_count":3,"citation_normalized_percentile":{"value":0.66447454,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"41","issue":"8","first_page":"857","last_page":"867"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9599999785423279},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.9810000061988831},{"id":"https://openalex.org/keywords/midostaurin","display_name":"midostaurin","score":0.7979999780654907},{"id":"https://openalex.org/keywords/flt3-mutation","display_name":"FLT3 mutation","score":0.6980000138282776},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.7279999852180481},{"id":"https://openalex.org/keywords/incremental-cost-effectiveness-ratio","display_name":"incremental cost-effectiveness ratio","score":0.7699999809265137},{"id":"https://openalex.org/keywords/best-supportive-care","display_name":"best supportive care","score":0.6240000128746033},{"id":"https://openalex.org/keywords/relapse-free-survival","display_name":"relapse-free survival","score":0.6809999942779541},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.7350000143051147},{"id":"https://openalex.org/keywords/low-dose-cytarabine","display_name":"low-dose cytarabine","score":0.9639999866485596},{"id":"https://openalex.org/keywords/nice-guidance","display_name":"NICE guidelines","score":0.4300000071525574},{"id":"https://openalex.org/keywords/technology-appraisal","display_name":"technology appraisal","score":0.3619999885559082},{"id":"https://openalex.org/keywords/risk-of-bias","display_name":"risk of bias","score":0.5059999823570251}],"concepts":[{"id":"https://openalex.org/C2779256446","wikidata":"https://www.wikidata.org/wiki/Q33959","display_name":"Nice","level":2,"score":0.7692571878433228},{"id":"https://openalex.org/C2776239401","wikidata":"https://www.wikidata.org/wiki/Q416451","display_name":"Azacitidine","level":5,"score":0.7011933922767639},{"id":"https://openalex.org/C524218345","wikidata":"https://www.wikidata.org/wiki/Q31218","display_name":"Health economics","level":3,"score":0.6923686265945435},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6766175627708435},{"id":"https://openalex.org/C2778091340","wikidata":"https://www.wikidata.org/wiki/Q15749950","display_name":"Quality of Life Research","level":3,"score":0.5954312086105347},{"id":"https://openalex.org/C12713177","wikidata":"https://www.wikidata.org/wiki/Q1900281","display_name":"Perspective (graphical)","level":2,"score":0.5909603834152222},{"id":"https://openalex.org/C2993296363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukaemia","level":2,"score":0.5025601387023926},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.487088680267334},{"id":"https://openalex.org/C138816342","wikidata":"https://www.wikidata.org/wiki/Q189603","display_name":"Public health","level":2,"score":0.4757547080516815},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3768472969532013},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.35181111097335815},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.13710856437683105},{"id":"https://openalex.org/C199360897","wikidata":"https://www.wikidata.org/wiki/Q9143","display_name":"Programming language","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C154945302","wikidata":"https://www.wikidata.org/wiki/Q11660","display_name":"Artificial intelligence","level":1,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.0},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001374","descriptor_name":"Azacitidine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D013673","descriptor_name":"Technology Assessment, Biomedical","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019057","descriptor_name":"Quality-Adjusted Life Years","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D060828","descriptor_name":"Induction Chemotherapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":6,"locations":[{"id":"doi:10.1007/s40273-023-01272-9","doi":"https://doi.org/10.1007/s40273-023-01272-9","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1007/s40273-023-01272-9","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40273-023-01272-9.pdf","source":{"id":"https://openalex.org/S43019230","display_name":"PharmacoEconomics","issn_l":"1170-7690","issn":["1170-7690","1179-2027"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PharmacoEconomics","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10322744","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10322744","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10322744/pdf/40273_2023_Article_1272.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacoeconomics","raw_type":"Text"},{"id":"pmid:37129774","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37129774","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PharmacoEconomics","raw_type":"Journal Article"},{"id":"pmh:oai:cris.maastrichtuniversity.nl:openaire/27b85c19-f127-469a-b713-54b4bbeef579","doi":null,"is_oa":true,"landing_page_url":"https://cris.maastrichtuniversity.nl/en/publications/27b85c19-f127-469a-b713-54b4bbeef579","pdf_url":null,"source":{"id":"https://openalex.org/S4306402616","display_name":"Research Publications (Maastricht University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I34352273","host_organization_name":"Maastricht University","host_organization_lineage":["https://openalex.org/I34352273"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Witlox, W, Grimm, S, Howick, J, Armstrong, N, Ahmadu, C, McDermott, K, Otten, T, Noake, C, Wolff, R & Joore, M 2023, 'Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy : An Evidence Review Group Perspective of a NICE Single Technology Appraisal', Pharmacoeconomics, vol. 41, no. 8, pp. 857-867. https://doi.org/10.1007/s40273-023-01272-9","raw_type":"info:eu-repo/semantics/review"},{"id":"pmh:oai:RePEc:spr:pharme:v:41:y:2023:i:8:d:10.1007_s40273-023-01272-9","doi":null,"is_oa":false,"landing_page_url":"http://link.springer.com/10.1007/s40273-023-01272-9","pdf_url":null,"source":{"id":"https://openalex.org/S4306401271","display_name":"RePEc: Research Papers in Economics","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I77793887","host_organization_name":"Federal Reserve Bank of St. Louis","host_organization_lineage":["https://openalex.org/I77793887"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article"},{"id":"pmh:um:oai:cris.maastrichtuniversity.nl:publications/27b85c19-f127-469a-b713-54b4bbeef579","doi":null,"is_oa":true,"landing_page_url":"https://cris.maastrichtuniversity.nl/en/publications/27b85c19-f127-469a-b713-54b4bbeef579","pdf_url":null,"source":{"id":"https://openalex.org/S4306402616","display_name":"Research Publications (Maastricht University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I34352273","host_organization_name":"Maastricht University","host_organization_lineage":["https://openalex.org/I34352273"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Pharmacoeconomics. Adis International Ltd","raw_type":"info:eu-repo/semantics/other"}],"best_oa_location":{"id":"doi:10.1007/s40273-023-01272-9","doi":"https://doi.org/10.1007/s40273-023-01272-9","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1007/s40273-023-01272-9","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40273-023-01272-9.pdf","source":{"id":"https://openalex.org/S43019230","display_name":"PharmacoEconomics","issn_l":"1170-7690","issn":["1170-7690","1179-2027"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PharmacoEconomics","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G5691402479","display_name":"Cognitive Behavioural Therapy: An overview of systematic reviews and meta-analyses","funder_award_id":"15/174/24","funder_id":"https://openalex.org/F4320319990","funder_display_name":"National Institute for Health and Care Research"}],"funders":[{"id":"https://openalex.org/F4320319990","display_name":"National Institute for Health and Care Research","ror":"https://ror.org/0187kwz08"},{"id":"https://openalex.org/F4320334661","display_name":"Health Technology Assessment Programme","ror":"https://ror.org/0187kwz08"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4367668398.pdf","grobid_xml":"https://content.openalex.org/works/W4367668398.grobid-xml"},"referenced_works_count":8,"referenced_works":["https://openalex.org/W2147860795","https://openalex.org/W2888758200","https://openalex.org/W2890371466","https://openalex.org/W2895485327","https://openalex.org/W2908841748","https://openalex.org/W2989764345","https://openalex.org/W3005960653","https://openalex.org/W3135647768"],"related_works":["https://openalex.org/W2539165044","https://openalex.org/W3199869802","https://openalex.org/W4311203322","https://openalex.org/W4413782974","https://openalex.org/W2541083871","https://openalex.org/W4404825069","https://openalex.org/W4405043196","https://openalex.org/W4224294081","https://openalex.org/W4405042739","https://openalex.org/W4283332558"],"abstract_inverted_index":{"The":[0,154,176,283,325,367],"National":[1],"Institute":[2],"for":[3,29,38,162,172,206,239,262,308,429,432],"Health":[4],"and":[5,33,57,96,107,165,189,204,232,285,343,361,369,457],"Care":[6],"Excellence":[7],"(NICE)":[8],"invited":[9],"the":[10,20,30,75,84,89,94,100,103,109,112,116,120,166,173,181,185,207,225,230,248,270,294,322,329,338,341,344,353,364,400,404,410,419],"manufacturer":[11],"(Celgene)":[12],"of":[13,19,35,41,111,136,168,180,252,281,331,340,346,348,380],"oral":[14,36,124,163,217,240,309,415],"azacitidine":[15,37,125,218,241,310,316,394,416],"(ONUREG),":[16],"as":[17,74,221,254,426],"part":[18],"Single":[21],"Technology":[22],"Appraisal":[23,117,412],"(STA)":[24],"process,":[25],"to":[26,72,157,219,357,418],"submit":[27],"evidence":[28,98],"clinical":[31,95,195,359],"effectiveness":[32],"cost-effectiveness":[34,97,289],"maintenance":[39,222,255,271,430],"treatment":[40,256,431],"acute":[42],"myeloid":[43],"leukaemia":[44],"(AML)":[45],"after":[46,449],"induction":[47,450],"therapy":[48,223,350,451],"compared":[49,243],"with":[50,65,244,390,444,452],"watch-and-wait":[51,312,386],"plus":[52,313,387],"best":[53,200],"supportive":[54,201],"care":[55,202],"(BSC)":[56,203],"midostaurin.":[58,245],"Kleijnen":[59],"Systematic":[60],"Reviews":[61],"Ltd,":[62],"in":[63,99,184,224,247,257,321,352,363,375,399,434,438],"collaboration":[64],"Maastricht":[66],"University":[67],"Medical":[68],"Centre+,":[69],"was":[70,159,260,300,317],"commissioned":[71],"act":[73],"independent":[76],"Evidence":[77],"Review":[78],"Group":[79],"(ERG).":[80],"This":[81],"paper":[82],"summarises":[83],"company":[85,177],"submission":[86],"(CS),":[87],"presents":[88],"ERG's":[90,326],"critical":[91],"review":[92],"on":[93],"CS,":[101],"highlights":[102],"key":[104],"methodological":[105],"considerations":[106],"describes":[108],"development":[110],"NICE":[113,406,411],"guidance":[114],"by":[115,194,293],"Committee.":[118],"In":[119],"QUAZAR":[121,354],"AML-001":[122,355],"trial,":[123],"significantly":[126],"improved":[127],"overall":[128],"survival":[129,234],"(OS)":[130],"versus":[131,141,311,319,385,397],"placebo:":[132],"median":[133,155],"OS":[134,231],"gain":[135],"9.9":[137],"months":[138,140],"(24.7":[139],"14.8":[142],"months;":[143],"hazard":[144],"ratio":[145,290],"(HR)":[146],"0.69":[147],"(95%":[148],"CI":[149],"0.55-0.86),":[150],"p":[151],"<":[152],"0.001).":[153],"time":[156],"relapse":[158,365],"also":[160],"better":[161],"azacitidine,":[164,191],"incidences":[167],"TEAEs":[169],"were":[170,237,266],"similar":[171,377],"two":[174,179],"arms.":[175],"excluded":[178],"comparators":[182],"listed":[183],"scope,":[186],"low-dose":[187],"cytarabine":[188],"subcutaneous":[190],"informed":[192],"only":[193,199,249],"expert":[196],"opinion,":[197],"leaving":[198],"midostaurin":[205,220,253,320,398],"FLT3-ITD":[208],"and/or":[209],"FLT3-TKD":[210],"(FLT3":[211],"mutation)-positive":[212],"subgroup.":[213,324,402],"An":[214],"ITC":[215],"comparing":[216],"appropriate":[226],"subgroup":[227],"demonstrated":[228],"that":[229,259],"relapse-free":[233],"(RFS)":[235],"HRs":[236],"favourable":[238],"when":[242],"However,":[246],"available":[250],"trial":[251,356],"AML":[258,433],"used":[261],"this":[263],"ITC,":[264],"subjects":[265],"not":[267,462],"randomised":[268],"at":[269,274],"phase,":[272],"but":[273,389],"induction,":[275],"which":[276],"posed":[277],"a":[278,297,376],"substantial":[279],"risk":[280],"bias.":[282],"revised":[284,368],"final":[286,370],"probabilistic":[287,378],"incremental":[288],"(ICER)":[291],"presented":[292],"company,":[295],"including":[296],"commercial":[298,420],"arrangement,":[299],"\u00a332,480":[301],"per":[302,382],"quality-adjusted":[303],"life":[304],"year":[305],"(QALY)":[306],"gained":[307,384],"BSC.":[314],"Oral":[315,393],"dominant":[318,396],"FLT-3":[323,401],"concerns":[327],"included":[328],"approach":[330],"modelling":[332],"haematopoietic":[333],"stem":[334],"cell":[335],"transplantation":[336],"(HSCT),":[337],"generalisability":[339],"population":[342],"number":[345],"cycles":[347],"consolidation":[349,455],"pre-treatment":[351],"UK":[358],"practice,":[360],"uncertainty":[362],"utility.":[366],"ERG":[371],"base":[372],"case":[373],"resulted":[374],"ICER":[379],"\u00a333,830":[381],"QALY":[383],"BSC,":[388],"remaining":[391],"uncertainty.":[392],"remained":[395],"After":[403],"second":[405],"appraisal":[407],"committee":[408],"meeting,":[409],"Committee":[413],"recommended":[414],"(according":[417],"arrangement),":[421],"within":[422],"its":[423],"marketing":[424],"authorisation,":[425],"an":[427],"option":[428],"adults":[435],"who":[436],"are":[437],"complete":[439,442],"remission,":[440],"or":[441,453,460],"remission":[443],"incomplete":[445],"blood":[446],"count":[447],"recovery,":[448],"without":[454],"treatment,":[456],"cannot":[458],"have":[459],"do":[461],"want":[463],"HSCT.":[464]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1}],"updated_date":"2026-11-03T10:50:19.383937","created_date":"2023-05-03T00:00:00"}